Creative Medical Technology Holdings (CELZ) Research & Development (2016 - 2026)

Creative Medical Technology Holdings (CELZ) has reported Research & Development for 9 consecutive years, with $459200.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 8.39% year-over-year to $459200.0 in Q2 2026; TTM through Jun 2026 was $2.0 million, a 12.28% decrease from a year earlier, with the FY2025 full-year figure at $2.3 million, down 5.87% from the prior year.
• Research & Development was $459200.0 for Q2 2026 at Creative Medical Technology Holdings, down from $541658.0 in the prior quarter.
• Over five years, Research & Development peaked at $5.4 million in Q4 2022 and troughed at $10000.0 in Q1 2022.
• A 5-year average of $772273.6 and a median of $486550.5 in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 10636.44% in 2022 and tumbled 93.49% in 2023, its largest moves.
• Over 5 years, Research & Development stood at $5.4 million in 2022, then plunged by 93.49% to $349408.0 in 2023, then surged by 35.04% to $471840.0 in 2024, then increased by 16.58% to $550077.0 in 2025, then retreated by 16.52% to $459200.0 in 2026.
• The last three Research & Development figures came in at $459200.0 (Q2 2026), $541658.0 (Q1 2026), and $550077.0 (Q4 2025), per Business Quant data.